Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies

Xian-Bao Li,a,b, Nv-Wei Cao,a,b, Xiu-Jie Chu,a,b, Hao-Yue Zhou,a,b, Hua Wang,a,b, Si-Jie Yu,c, Dong-Qing Ye,a,b and Bao-Zhu Li,a,b

aDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China; bAnhui Provincial Laboratory of Inflammatory and Immune Diseases, Hefei, Anhui, China; cDepartment of Clinical Medicine “5 + 3” Integration, Second Clinical Medical College, Anhui Medical University, Hefei, Anhui, China

ABSTRACT
Objective: To investigate the effect of antimalarials on cancer risk in patients with systemic lupus erythematosus (SLE).
Methods: PubMed, EMBASE, Web of Science, and the Cochrane Library were searched from their inception to October 3, 2020. Relative risk (RR) with 95% confidence intervals (CI) was used to evaluate the results. Subgroup analyses were used to assess heterogeneity. A funnel plot was used to explore publication bias. STATA was applied for all analyses.
Results: A total of nine studies consisted of four nested case–control, two case–cohort and three cohort studies were included. The results showed that antimalarials might reduce the risk of cancer in SLE (RR = 0.68, 95%CI: 0.55–0.85). In the subgroup analysis of four nested case–control and two case–cohort studies, the pooled RR was estimated as 0.69 (95% CI: 0.60–0.80). In four studies about hydroxychloroquine, the pooled RR was estimated as 0.70 (95% CI: 0.53–0.93). Antimalarials might reduce the risk of cancer in SLE among the Asian population (RR = 0.66; 95% CI: 0.49–0.88) (I² = 43.1%, p = .173). And the consistent result was also found in SLE from multiple centres (RR = 0.72; 95%CI: 0.60–0.87) (I² = 0%, p = .671). On disease course-and comorbidities-matched studies, the pooled RRs were 0.69 (95% CI: 0.52–0.93) and 0.59 (95% CI: 0.46–0.75), respectively.
Conclusion: Results of this meta-analysis showed that antimalarial drugs might be protective factors for cancer in SLE. Hydroxychloroquine might be a protective factor for cancer in SLE patients.

KEY MESSAGES
- Antimalarials might be protective factors for cancer in SLE.
- Hydroxychloroquine might be a protective factor for cancer in SLE patients.
- The first article to perform the meta-analysis of antimalarial drugs on the risk of cancer in SLE patients.

Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease that often occurs in women and affects multiple organs [1,2]. Patients with SLE have a higher mortality rate than the general population [3,4]. The main causes of death in SLE patients are infection, cardiovascular disease, and cancer [5,6]. Compared to the general population, previous studies have shown a higher incidence of cancer in SLE patients, such as lymphoma, vulva cancer, lung cancer, thyroid cancer, cervical cancer, and kidney cancer [7–11].

At present, corticosteroids, hydroxychloroquine (HCQ), and immunosuppressants are most commonly used in the clinical treatment of SLE. Immunoregulatory and anti-inflammatory effects of antimalarials have beneficial effects on the outcomes

CONTACT Bao-Zhu Li lbz88730@163.com Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China; Dong-Qing Ye ydyq@ahmu.edu.cn Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
of SLE patients. It might improve the survival and remission rates [12], ameliorate disease activity [13], reduce accrual of new disease-related damage [14,15], and decrease infection rates [16]. HCQ and chloroquine (CQ) are autophagy inhibitors that inhibit autophagy by affecting lysosomes [17]. Current studies have found that autophagy can regulate cell cycle progression, thus playing an important role in cancer [18–20].

Some studies have reported relationships between antimalarials and cancer in SLE patients, but the results were controversial. Ruiz-Irastorza G put forward a hypothesis that antimalarial drugs might have a protective effect on cancer in SLE patients [21]. But Dey found that the risk of tumours in SLE patients was not related to drug, dose, or disease duration [22]. Therefore, a meta-analysis is needed to explore whether taking antimalarials is associated with the risk of cancer in SLE patients.

Methods

Data sources and searches

This review was conducted by PRISMA guidelines [23] (Supplementary Material 1). We systematically searched EMBASE, Web of Science, PubMed, and the Cochrane Library from their inception to the end of October 3, 2020. The search strategy included the MeSH and text words as ((lupus erythematosus, systemic [MeSH Terms] OR systemic lupus erythematosus OR lupus OR SLE) AND (neoplasms [MeSH Terms] OR carcinoma [MeSH Terms] OR cancer OR carcinoma OR malignancy OR neoplasm OR neoplasia OR tumour)) AND (antimalarials [MeSH Terms] OR hydroxychloroquine [MeSH Terms] OR chloroquine [MeSH Terms] OR antimalarial agents OR antimalarial drugs OR antimalarials OR hydroxychloroquine OR HCQ OR chloroquine). In addition, relevant articles outside the search list were manually searched.

Study selection

Studies were eligible if they met the following criteria: (1) All included patients met the American College of Rheumatology criteria or international classification of disease criteria for the diagnosis of SLE. (2) The study provided the cancer outcomes in SLE patients who took antimalarials (antimalarials+) and controls who did not take antimalarials (antimalarials−). (3) The study was designed by cohort, case–cohort, or nested case–control. The study would be excluded if met following contents: (1) The outcome was cancer with precancerous lesions. (2) The included patients had cutaneous lupus erythematosus.

Data extraction and quality assessment

The relevant information, including first author, research period, year of publication, type of study, study population, disease course, SLE and cancer diagnostic criteria, the number of SLE patients taking antimalarials, and the number of people who developed cancer in each group, were extracted independently by two reviewers (XBL and NWC). In these studies, disease duration was defined as the duration from the date of SLE diagnosis to that of their cancer diagnosis [22]. When these reviewers had inconsistent opinions on an article, disagreements were resolved through discussions with another reviewer (XJC). Two reviewers (XBL and NWC) independently evaluated the risk of potential bias by the Newcastle–Ottawa Scale (NOS). Disagreements were resolved through discussions with another reviewer (XJC).

Data synthesis and analysis

Excel 2019 and STATA 11.0 (Stata Corp. LP, College Station, TX, USA) were used for data extraction and meta-analysis. Data was expressed by relative risk (RR) with its associated 95% confidence intervals (CI). Inverse variance with random effects models was used for data analysis. Inconsistency ($I^2$) was calculated to determine heterogeneity. $I^2 < 50\%$ indicated that the heterogeneity of included studies was acceptable. Factors, such as research type, region, types of antimalarials, gender, age, disease course, and comorbidities may induce heterogeneity. If included studies reported information about these factors, subgroup analyses were conducted to explore sources of heterogeneity. Sensitivity analysis was used to assess the robustness of estimates. Funnel plots, Egger's test, and Begg's test were applied to evaluate publication bias. $p < .05$ was defined as statistically significant.

Results

Study selection

A total of 2737 articles were searched at first from four databases. Two thousand six hundred and eighty-nine articles were excluded after deleting duplication and screening titles and abstracts. After reviewing the full text of the remaining, 40 studies were excluded (lack of relevant data, $n = 6$; review, case report, the
meeting, case–control, n = 15; not control, n = 1; not related, n = 16; duplicates, n = 2), and eight studies were finally included [21,24–30]. One study was also included after manually searching [22]. In the end, a total of nine articles were included in this meta-analysis (Figure 1).

**Study characteristics**

The characteristics of these included studies were detailed in Table 1. Three cohorts, four nested case–control, and two case–cohort studies were included. Four studies showed the effects of HCQ on cancer in SLE, while five did not state specific types of antimalarials. Three included studies were conducted in Asian populations, three were in European populations, and the rest were in multiple populations. Among included studies, four matched the age and gender of case and control groups [22,25,29,30], three matched the course of disease in two groups [22,25,28], and two matched comorbidities of case and control groups [25,29]. Other detailed information was shown in Supplemental Table 1.

**Quality of included studies**

All NOS scores ≥7 indicated the high quality of all included studies (Table 2). All groups in each study used the same survey methods. None of the controls had a history of disease in case–control studies, and none of the subjects developed the disease under study at the beginning of cohort studies. Cases were well-represented in case–control studies, and exposures were representative in cohort studies. The investigation of exposure and the determination of outcome had reliable sources.

**Antimalarials reduce the risk of cancer in SLE**

Results showed that the risk of cancer in the antimalarials+ group was lower than that in the antimalarials− group (RR = 0.68; 95%CI: 0.55–0.85) ($I^2 = 45.3\%$, $p = .067$) (Figure 2). In four nested case–control and two case–cohort studies, the risk of cancer was lower in the antimalarials+ group than that in the antimalarials− group (RR = 0.69; 95%CI: 0.60–0.80) ($I^2 = 7.6\%; p = .365$) (Figure 2). However, in three cohort studies, there was no significant difference between the two groups (RR = 0.27; 95%CI: 0.04–1.71) ($I^2 = 78.7\%; p = .009$) (Figure 2).

**Subgroup analysis**

Among the Asian population, the antimalarials+ group had a lower risk of cancer (RR = 0.66; 95%CI: 0.49–0.88) ($I^2 = 43.1\%; p = .173$). And a consistent result was also found in SLE from multiple centres (RR = 0.72; 95%CI: 0.60–0.87) ($I^2 = 0\%$, $p = .671$). Whereas no significant difference was found among the European population (RR = 0.28; 95%CI: 0.04–2.09) ($I^2 = 81.4\%; p = .005$) (Figure 3).

On studies matching disease course, it was found that the risk of cancer in the antimalarials+ group was lower than that in the antimalarials− group.
**Table 1.** Characteristics of included studies.

| Author, Year | Drug | Design | Region | SLE diagnostic criteria | Cancer diagnostic criteria | Cancer/control female age at SLE diagnosis | Cancer/control male age at SLE diagnosis | Matched characteristics | No. of cancer in use drug/No. of all in use drug | No. of cancer in control/No. of all in control | Study period |
|--------------|------|--------|--------|-------------------------|-----------------------------|------------------------------------------|------------------------------------------|------------------------|-----------------------------------------------|-----------------------------------------------|-------------|
| Guo JY 2020 | HCQ  | Nested case–control | Asia | ACR1997 | Histological analyses | 49/192 | 41/33 | 60/60 months | Age, gender, complications, disease course | 29/184 | 22/71 | 2010–2019 |
| Cai SZ 2020 | HCQ  | Nested case–control | Asia | ICD-9 710.0 | ICD-9 140-208 | Tissue proof | 295/1180 | 44.8/44 | Age, gender, complications | 289/1517 | 41/133 | 1997–2013 |
| Hsu CY 2017 | HCQ  | Nested case–control | Asia | ACR1997 | Tissue proof | NA | NA | NA | Age, gender, disease course | 24/91 | 9/36 | 1976–2010 |
| Dey D 2013  | HCQ  | Nested case–control | Europe | ACR1997 | Histological or autopsy reports | NA | NA | NA | Disease course | 20/39 | 23/40 | 1976–2010 |
| Bernatsky S 2020 | Antimalarial | Cohort | North America, Europe and Asia | ACR1997 | Medical files including pathology reports | 142/67 | 34/42 | NA | 2010–2019 |
| Wadstrom H 2017 | Antimalarial | Cohort | Europe | ICD-8 734.1, ICD-9 710.0, ICD-10 M32 | Histology or cytology analyses | 5/4971 | NA | NA | 2010–2013 |
| Bernatsky S 2014 | Antimalarial | Case-cohort | North America, Europe and Asia | ACR1997 Regional registry OR medical chart | 60/4511 | 45.2/38.5 | 6.2/6.2 years | 2010–2013 |
| Bernatsky S 2008 | Antimalarial | Case-cohort | North America, Europe and Asia | ACR1997 OR clinical criteria | 221/489 | 42/35 | 1/1 years | 2010–2013 |
| Ruiz-Irastorza, G 2017 | Antimalarial | Cohort | Europe | ACR1997 Radiological and/or histological | 142/67 | 34/42 | NA | 2010–2013 |

HCQ: hydroxychloroquine; NA: not applicable; ACR: American College of Rheumatology criteria; ICD: International Classification of Diseases.

†Mean age at diagnosis [drug-use/disease-free].

---

**Table 2.** Methodological quality of studies included in the meta-analysis.

| References | Cases definition | Representativeness of cases | Selection of controls | Definition of controls | Control for important factor or additional factorsa | Ascertainment of exposure | Same method of ascertainment for participants | Non-responsive rate | Total quality scores |
|------------|-----------------|-----------------------------|----------------------|------------------------|---------------------------------|----------------------|-----------------------------------------------|-------------------|----------------------|
| Guo JY [23] | Star             | Star                         | -                    | Star                   | Star                            | Star                 | Star                                         | Star              | 7                    |
| Cai, SZ [28] | Star             | Star                         | -                    | Star                   | Star                            | Star                 | Star                                         | Star              | 9                    |
| Hsu CY [27] | Star             | Star                         | -                    | Star                   | Star                            | Star                 | Star                                         | Star              | 7                    |
| Bernatsky S [25] | Star             | Star                         | -                    | Star                   | Star                            | Star                 | Star                                         | Star              | 7                    |
| Berrnatsky S [26] | Star             | Star                         | -                    | Star                   | Star                            | Star                 | Star                                         | Star              | 8                    |
| Dey D [29] | Star             | Star                         | -                    | Star                   | -                               | Star                 | Star                                         | Star              | 7                    |

Cohort studies

| References | Cases definition | Representativeness of the exposed cohort | Selection of the unexposed cohort | Assessment of exposure | Absence of outcome at the start of study | Outcome assessment | Follow-up period | Adequacy of follow-up | Total quality scores |
|------------|-----------------|------------------------------------------|----------------------------------|------------------------|------------------------------------------|-------------------|-----------------|---------------------|----------------------|
| Bernatsky, S [24] | Star             | Star                                     | Star                             | Star                   | Star                                     | Star              | Star            | Star                | 7                    |
| Wadstrom H [21] | Star             | Star                                     | Star                             | Star                   | Star                                     | Star              | Star            | Star                | 7                    |
| Ruiz-Irastorza, G [22] | Star             | Star                                     | Star                             | Star                   | Star                                     | Star              | Star            | Star                | 7                    |

aStudies that controlled for age and sex received 1 star. Studies that controlled for other risk factors received an additional star.
(RR = 0.69; 95% CI, 0.52–0.93) ($I^2 = 37.1\% ; p = .204$) (Supplemental Figure 1(a)). On studies matching complications, the pooled RR was 0.59 (95% CI: 0.46–0.75) ($I^2 = 0\% ; p = .490$) (Supplemental Figure 1(b)). On studies matching age and gender, the pooled RR was 0.70 (95% CI, 0.53–0.93) ($I^2 = 43.1\% ; p = .153$) (Supplemental Figure 1(c)).

At present, HCQ is the most common antimalarial drug used to treat SLE. Results showed that HCQ reduced the risk of cancer in SLE patients (RR = 0.70; 95% CI: 0.53–0.93) ($I^2 = 43.1\% ; p = .153$) (Figure 4). In five studies that did not state specific types of antimalarials, the result showed the pooled RR was 0.61 (95% CI: 0.40–0.95) ($I^2 = 57.3\% , p = .053$) (Figure 4).

**Funnel figure and sensitivity analysis**

Results of Egger’s test ($t = –0.88$) and Begg’s test ($Z = 0.52$) indicated no significant publication bias (Supplemental Figure 2). Removing one article each time, overall RRs were around 0.68 (Supplemental Figure 3). It indicated that the results of this study were robust and not affected by any single study.

**Discussion**

To the best of our knowledge, this is the first meta-analysis examining the risk of cancer in SLE patients taking antimalarials. Antimalarials might reduce cancer risk in SLE patients. In particular, HCQ might reduce the risk of cancer in SLE patients. In four nested case–control and two case–cohort, SLE patients in the antimalarials+ group had a lower risk of cancer than those in antimalarials– group. But the difference was not found in subgroup analysis in cohort studies.

Three phase I trials of HCQ combined with vorinostat, bortezomib and temsirolimus in the treatment of cancer showed that the combination therapy had anti-tumour activity and had potential effects on the treatment of tumours [31–33]. In a meta-analysis of seven clinical trials, autophagy-inhibitor-based therapy (HCQ or chloroquine combination therapy) had a better response in cancer treatment than chemotherapy or radiation without inhibiting autophagy [18]. Various published studies reported the association between the risk of cancer and antimalarials in patients with SLE. In a previous study with 14 cohorts, a reduced risk (adjusted hazard ratios = 0.55) was observed for lung cancer in SLE patients with cumulative use of antimalarial drugs over 5 years but did not reach statistical significance [34]. Feldman CH found a trend that people receiving HCQ had a lower rate of cervical dysplasia and cervical cancer compared with those who receive immunosuppressive drugs [35]. In our large-sample
and multi-center meta-analysis, it was also indicated that antimalarials might have a protective effect on the risk of cancer in SLE.

The antitumor properties of antimalarials may be related to their promotion of macrophage transformation, inhibition of autophagy, and promotion of...
apoptosis [36]. HCQ and CQ are weak binary bases. By increasing the pH of lysosomes and other intracellular compartments, these drugs interfered with the function of phagocytosis and antigen presentation to T cells [37,38]. The increase of pH value in lysosomes would promote the transformation of tumour-associated macrophages (TAMS) from M2 phenotype to M1 phenotype [39]. M2-TAM can block immune monitoring and increase tumour progression and metastasis, while M1-TAM can release nitrogen oxide and interferon-γ to kill tumours [40]. Chloroquine exerts an anti-tumour effect by transforming tumour-promoting M2-TAM into tumour-suppressing M1-TAM. Current studies showed that autophagy played a different role in different stages of cancer [41]. Initially, inhibiting autophagy may encourage healthy cells to develop cancer [42]. But, in later stages of cancer, autophagy can enhance tumour progression and metastasis, and enhance the ability to respond to adverse microenvironmental conditions, such as hypoxia and nutritional deficiencies [43,44]. Inhibition of autophagy may increase environmental or treatment-induced stress to promote cancer cell death [45,46]. One reason for the survival of cancer cells is the ability to escape apoptosis. Beclin-2 protein can block mitochondrial apoptosis [47]. Antimalarial drugs promote mitochondrial apoptosis through block the apoptosis regulator (Beclin-2 protein), thereby promoting the apoptosis of cancer cells [48].

Several advantages were in this study. First, the data of our study was retrieved from prospective studies, including cohort studies, nested case–control studies, and case–cohort studies. The collection of exposure data in prospective studies is obtained by the investigator personally, and there is generally no recall bias, so the data is reliable. In prospective studies, because the exposure occurs before the occurrence of the disease and the causal time sequence is clear, the ability to test the aetiological hypothesis is stronger and the results are more reliable. Second, a large sample size of 14810 was included in this meta-analysis, indicating the high credibility of the results. Third, with all NOS scores ≥7, the qualities of studies included were relatively high. It demonstrated the high reliability and validity of the results.

However, our study has several limitations related to the quality of data in original sources. First, we were unable to fully assess the risk of bias in certain situations because the published studies did not provide enough details. Due to the lack of necessary data on malignant tumour types and drug dosages, our results may be underestimated. Therefore, the drug dosage and the drug situation for each cancer should be reported in further studies. Second, among different research types, the results of subgroups were inconsistent. Therefore, the results should be further verified in the future. Third, our data in this study came from observational studies, and we need to be cautious when interpreting the evidence of observational studies, because the results of observational studies are more biased than the results of randomized controlled trials. Therefore, more experiments are needed to prove this conclusion in the future.

Conclusion
The result of this meta-analysis showed that antimalarials might be protective factors for cancer in SLE. HCQ might be a protective factor for cancer in SLE patients.

Acknowledgements
Thank Li B.Z. for her guidance and critical advice on the science of this article.

Disclosure statement
The authors declare that they have no conflicts of interest concerning this article. Our research is not registered elsewhere.

Funding
This study was supported by the National Natural Science Foundation of China (81803310), the Grants for Scientific Research of BSKY from Anhui Medical University (XJ201619), the Emergency Research Project of Novel Coronavirus Infection of Anhui Medical University (YJGG202003), and Undergraduate Innovation and Entrepreneurship Training Program in Anhui Province (S201910366064).

ORCID
Bao-Zhu Li http://orcid.org/0000-0001-8081-9857

References
[1] Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–2121.
[2] Wu Q, Zhou J, Yuan ZC, et al. Association between IL-37 and systemic lupus erythematosus risk. Immunol Invest. 2021;Jan 17:1–12.
[3] Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550–2557.
[4] Urowitz MB, Gladman DD, Tom BD, et al. Changing patterns in mortality and disease outcomes for
patients with systemic lupus erythematosus. J Rheumatol. 2008;35(11):2152–2158.

[5] Lorenzo-Vizcaya A, Isenberg D. Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom. Lupus. 2021;30(5):702–706.

[6] Tselios K, Gladman DD, Sheane BJ, et al. All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971–2013). Ann Rheum Dis. 2019;78(6):802–806.

[7] Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130–135.

[8] Rees F, Doherty M, Grainge M, et al. Burden of comorbidity in systemic lupus erythematosus in the UK, 1999–2012. Arthritis Care Res. 2016;68(6):819–827.

[9] Kim SC, Glynn RJ, Giovannucci E, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015;74(7):1360–1367.

[10] Tallbacka KR, Pettersson T, Pukkala E. Increased incidence of cancer in systemic lupus erythematosus: a Finnish cohort study with more than 25 years of follow-up. Scand J Rheumatol. 2018;47(6):461–464.

[11] Yang Y, Li X, Li B, et al. Associations between TNFSF4 gene polymorphisms (rs2205960 G > A, rs704840 T > G and rs8446484 G > A) and susceptibility to autoimmune diseases in Asians: a meta-analysis. Immunol Invest. 2021;50(2–3):184–200.

[12] Hsu CY, Lin YS, Cheng TT, et al. Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus. Rheumatology. 2018;57(10):1743–1751.

[13] Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011;7(12):718–729.

[14] Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20–28.

[15] Bruce IN, O’Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann Rheum Dis. 2015;74(9):1706–1713.

[16] Yuan Q, Xing X, Lu Z, et al. Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: a systematic review and Meta-analysis of observational studies. Semin Arthritis Rheum. 2020;50(5):1022–1039.

[17] Yang YP, Hu LF, Zheng HF, et al. Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol Sin. 2013;34(5):625–635.

[18] Xu R, Ji Z, Xu C, et al. The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: a systematic review and meta-analysis. Medicine. 2018;97(46):e12912.

[19] Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70(6):1608–1621.

[20] Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol. 2009;625(1–3):220–233.

[21] Ruiz-Irastorza G, Ugarte A, Egurbide MV, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis. 2007;66(6):815–817.

[22] Dey D, Kenu E, Isenberg DA. Cancer complicating systemic lupus erythematosus—a dichotomy emerging from a nested case-control study. Lupus. 2013;22:919–927.

[23] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement. PLOS Med. 2009;6(7):e1000097.

[24] Wadström H, Arkema EV, Sjöwall C, et al. Cervical neoplasia in systemic lupus erythematosus: a nationwide study. Rheumatology. 2017;56(4):613–619.

[25] Guo J, Ren Z, Li J, et al. The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study. Arthritis Res Ther. 2020;22(1):159.

[26] Bernatsky S, Ramsey-Goldman R, Urowitz MB, et al. Cancer risk in a large inception SLE cohort: effects of demographics, smoking, and medications. Arthritis Care Res. 2020;Aug 19:10.1002/acr.24425.

[27] Bernatsky S, Ramsey-Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73(1):138–142.

[28] Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis. 2008;67(1):74–79.

[29] Hsu C-Y, Lin M-S, Su Y-J, et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology. 2017;56(4):620–628.

[30] Cai S, Perng W-T, Huang JY, et al. Neoplasm risk in rheumatic diseases has no correlation with conventional synthetic disease-modifying anti-rheumatic drugs usage—a population-based nested case-control study. Front Med. 2020;7:473.

[31] Mahalingam D, Mita M, Sarantopoulos J, et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy. 2014;10(8):1403–1414.

[32] Vogl DT, Stadtmuere EA, Tan KS, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy. 2014;10(8):1380–1390.
[33] Rangwala R, Chang YC, Hu J, et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy. 2014;10(8):1391–1402.

[34] Bernatsky S, Ramsey-Goldman R, Petri M, et al. Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus. J Rheumatol. 2018;45(3):393–396.

[35] Feldman CH, Liu J, Feldman S, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs. Lupus. 2017;26(7):682–689.

[36] Plantone D, Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig. 2018;38(8):653–671.

[37] Pasquier B. Autophagy inhibitors. Cell Mol Life Sci. 2016;73(S):985–1001.

[38] Wallace DJ, Gudsoorkar VS, Weisman MH, et al. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8(9):522–533.

[39] Chen D, Xie J, Fiskesund R, et al. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat Commun. 2018;9(1):873.

[40] Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399–416.

[41] Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528–542.

[42] Galluzzi L, Pietrocola F, Bravo-San Pedro JM, et al. Autophagy in malignant transformation and cancer progression. EMBO J. 2015;34(7):856–880.

[43] Shi TT, Yu XX, Yan LJ, et al. Research progress of hydroxychloroquine and autophagy inhibitors on cancer. Cancer Chemother Pharmacol. 2017;79(2):287–294.

[44] Amaravadi R, Kimmelman AC, White E. Recent insights into the function of autophagy in cancer. Genes Dev. 2016;30(17):1913–1930.

[45] White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12(6):401–410.

[46] Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–166.

[47] Moldoveanu T, Czabotar PE. BAX, BAK, and BOK: a coming of age for the BCL-2 family effector proteins. Cold Spring Harb Perspect Biol. 2020;12(4):a036319.

[48] Martinez GP, Zabaleta ME, Di Giulio C, et al. The role of chloroquine and hydroxychloroquine in immune regulation and diseases. Curr Pharm Des. 2020;26(35):4467–4485.